The University of Chicago Header Logo

Connection

George Bakris to Blood Glucose

Back to Details
This is a "connection" page, showing publications George Bakris has written about Blood Glucose.
George Bakris
Connection Strength
2.798
Blood Glucose
  1. Glycemic control and cardiovascular disease in chronic kidney disease. Curr Diab Rep. 2009 Jun; 9(3):243-8.
    View in: PubMed
    Score: 0.257
  2. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7.
    View in: PubMed
    Score: 0.216
  3. Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023 10 01; 46(10):1740-1746.
    View in: PubMed
    Score: 0.174
  4. Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2023 08 02; 69(8):777-784.
    View in: PubMed
    Score: 0.172
  5. Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care. J Fam Pract. 2022 07; 71(6 Suppl):S88-S93.
    View in: PubMed
    Score: 0.159
  6. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S125-S143.
    View in: PubMed
    Score: 0.154
  7. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S83-S96.
    View in: PubMed
    Score: 0.154
  8. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6.
    View in: PubMed
    Score: 0.132
  9. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
    View in: PubMed
    Score: 0.092
  10. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9.
    View in: PubMed
    Score: 0.089
  11. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75.
    View in: PubMed
    Score: 0.088
  12. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
    View in: PubMed
    Score: 0.076
  13. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56.
    View in: PubMed
    Score: 0.073
  14. Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):51-8.
    View in: PubMed
    Score: 0.067
  15. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5):529-36.
    View in: PubMed
    Score: 0.062
  16. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
    View in: PubMed
    Score: 0.058
  17. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
    View in: PubMed
    Score: 0.058
  18. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006 Aug; 48(2):219-24.
    View in: PubMed
    Score: 0.052
  19. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul; 99(7):431-6.
    View in: PubMed
    Score: 0.052
  20. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 May; 8(5):351-6; quiz 357-8.
    View in: PubMed
    Score: 0.052
  21. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications. 2005 Mar-Apr; 19(2):74-9.
    View in: PubMed
    Score: 0.048
  22. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36.
    View in: PubMed
    Score: 0.047
  23. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5.
    View in: PubMed
    Score: 0.044
  24. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023 10 01; 46(10):e151-e199.
    View in: PubMed
    Score: 0.043
  25. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2023 08 02; 69(8):808-868.
    View in: PubMed
    Score: 0.043
  26. Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022 08 01; 28(8):e301-e307.
    View in: PubMed
    Score: 0.040
  27. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
    View in: PubMed
    Score: 0.033
  28. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
    View in: PubMed
    Score: 0.027
  29. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
    View in: PubMed
    Score: 0.023
  30. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
    View in: PubMed
    Score: 0.023
  31. Diabetic nephropathy. Dis Mon. 1993 Aug; 39(8):573-611.
    View in: PubMed
    Score: 0.021
  32. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
    View in: PubMed
    Score: 0.021
  33. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):e61-99.
    View in: PubMed
    Score: 0.018
  34. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):1419-23.
    View in: PubMed
    Score: 0.018
  35. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):e1-e47.
    View in: PubMed
    Score: 0.018
  36. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):793-8.
    View in: PubMed
    Score: 0.018
  37. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
    View in: PubMed
    Score: 0.016
  38. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008 Jul; 52(1):30-6.
    View in: PubMed
    Score: 0.015
  39. The editor's roundtable: revisiting the role of beta blockers in hypertension. Am J Cardiol. 2007 Jul 15; 100(2):253-67.
    View in: PubMed
    Score: 0.014
  40. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 Jul; 24(7):759-63.
    View in: PubMed
    Score: 0.014
  41. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. Curr Pharm Des. 2006; 12(13):1567-79.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.